N-Acetyl-Cysteine (NAC) in Early Phase Schizophrenia Spectrum Psychosis (NACPSY)
Effects of Oral N-Acetyl-Cysteine (NAC) in the Early Phase of Schizophrenia Spectrum Psychosis: Randomized, Parallel, Double- Blind, Placebo Controlled Trial
Sponsor: Beth Israel Deaconess Medical Center
A PHASE2 clinical study on Schizophrenic Psychoses, this trial is completed. The trial is conducted by Beth Israel Deaconess Medical Center and has accumulated 7 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Jul 2017 — Jun 2018 [monthly]
Completed PHASE2
Phase: PHASE4 → PHASE2
▶ Show 2 earlier versions
-
Feb 2017 — Jul 2017 [monthly]
Completed PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE4
First recorded
May 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Beth Israel Deaconess Medical Center
- Center de Neurosciences Psychiatrique, Lausanne, Switzerland
For direct contact, visit the study record on ClinicalTrials.gov .